Cardiovascular Safety and State-of-the-art Development Issues 2012: Type 2 Diabetes Mellitus Medications, QT, Benefit/Risk Assessment, Arrhythmias, Thrombosis, and Cardiotoxicity

Posted:
19
March 2012

Join Richmond Pharmacology next month for the DIA Cardiovascular Safety and State-of-the-art Development Issues meeting taking place 17 to 18 April 2012 in Washington.The meeting will address present issues surrounding Type 2 Diabetes Mellitus Medications, QT, Benefit/Risk Assessment, Arrhythmias, Thrombosis, and Cardiotoxicity during a series of debate-style presentations from international industry, academic, and regulatory speakers.Dr Jorg Taubel's current research is concerned with the cardiovascular effects of meals, insulin and C-peptide in Caucasian and Japanese populations. He will be presenting some of his most recent findings on Day 2 (18 Apr 2012), covering the following topics of discussion:Session 6, CV Safety Track at 10h30:

  • Moxifloxacin effect on the QTc interval in fed and fasted states in Thorough QT studies

Session 4, Diabetes Track at 11h00:

  • Insulin does not prolong the QT interval in thorough QT studies performed in healthy volunteers

For further information on Richmond Pharmacology�s specialist Cardiovascular Safety expertise or to request a copy of our latest TQT publication, contact a member of our Business Development team today. Alternatively we hope to see you in the US next month!

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more